GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Strategic Ventures (OTCPK:NUGS) » Definitions » Sloan Ratio %

Cannabis Strategic Ventures (Cannabis Strategic Ventures) Sloan Ratio % : -7.16% (As of Jun. 2020)


View and export this data going back to 2005. Start your Free Trial

What is Cannabis Strategic Ventures Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Cannabis Strategic Ventures's Sloan Ratio for the quarter that ended in Jun. 2020 was -7.16%.

As of Jun. 2020, Cannabis Strategic Ventures has a Sloan Ratio of -7.16%, indicating the company is in the safe zone and there is no funny business with accruals.


Cannabis Strategic Ventures Sloan Ratio % Historical Data

The historical data trend for Cannabis Strategic Ventures's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Strategic Ventures Sloan Ratio % Chart

Cannabis Strategic Ventures Annual Data
Trend Dec13 Dec14 Mar16 Mar17 Mar18 Mar19 Mar20
Sloan Ratio %
Get a 7-Day Free Trial - - -695.83 -661.39 11.22

Cannabis Strategic Ventures Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -97.24 -79.71 -1.80 -7.16

Competitive Comparison of Cannabis Strategic Ventures's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Strategic Ventures's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannabis Strategic Ventures's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Strategic Ventures's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Cannabis Strategic Ventures's Sloan Ratio % falls into.



Cannabis Strategic Ventures Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Cannabis Strategic Ventures's Sloan Ratio for the fiscal year that ended in Mar. 2020 is calculated as

Sloan Ratio=(Net Income (A: Mar. 2020 )-Cash Flow from Operations (A: Mar. 2020 )
-Cash Flow from Investing (A: Mar. 2020 ))/Total Assets (A: Mar. 2020 )
=(-9.055--7.643
--3.403)/17.738
=11.22%

Cannabis Strategic Ventures's Sloan Ratio for the quarter that ended in Jun. 2020 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Jun. 2020 )
=(-10.478--8.562
--0.673)/17.357
=-7.16%

Cannabis Strategic Ventures's Net Income for the trailing twelve months (TTM) ended in Jun. 2020 was -4.525 (Sep. 2019 ) + -1.243 (Dec. 2019 ) + -3.287 (Mar. 2020 ) + -1.423 (Jun. 2020 ) = $-10.48 Mil.
Cannabis Strategic Ventures's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2020 was -2.796 (Sep. 2019 ) + -2.049 (Dec. 2019 ) + -2.368 (Mar. 2020 ) + -1.349 (Jun. 2020 ) = $-8.56 Mil.
Cannabis Strategic Ventures's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2020 was -0.253 (Sep. 2019 ) + -0.262 (Dec. 2019 ) + -0.152 (Mar. 2020 ) + -0.006 (Jun. 2020 ) = $-0.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cannabis Strategic Ventures  (OTCPK:NUGS) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Jun. 2020, Cannabis Strategic Ventures has a Sloan Ratio of -7.16%, indicating the company is in the safe zone and there is no funny business with accruals.


Cannabis Strategic Ventures Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Cannabis Strategic Ventures's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cannabis Strategic Ventures (Cannabis Strategic Ventures) Business Description

Traded in Other Exchanges
N/A
Address
9350 Wilshire Boulevard, Suite 203, Beverly Hills, CA, USA, 90212
Cannabis Strategic Ventures focuses on the medical and legal recreational cannabis sector. It provides temporary, permanent, and long-term staffing solutions, employment and human resources consulting to the legal Cannabis sector.
Executives
Gordon Samson director, officer: Chief Financial Officer 9595 WILSHIRE BLVD., SUITE 900 BEVERLY HILLS CA 90212
Dane Brown director, officer: VP, Corporate Development 9595 WILSHIRE BOULEVARD, SUITE 900 BEVERLY HILLS CA 90212
Christopher G Foster director, officer: CFO, Secretary & Treasurer 5151 E. BROADWAY, SUITE 1600, TUCSON AZ 85711
Robert Hoegler director, 10 percent owner, officer: President #604 7040 GRANVILLE AVENUE RICHMOND A1 V6Y 3W5
Floyd Flaman director, 10 percent owner, officer: SECRETARY/TREASURER 5621 52ND STREET DELTA A1 V4K 2C7
Scott Marshall director, 10 percent owner, officer: President 2435 WEST 7TH AVENUE VANCOUVER A1 00000

Cannabis Strategic Ventures (Cannabis Strategic Ventures) Headlines

From GuruFocus

Cannabis Strategic Ventures Highlights Record Results in 2019

By Marketwired Marketwired 12-23-2019